CL2023001781A1 - Mutaciones en regiones constantes de anticuerpos felinos - Google Patents

Mutaciones en regiones constantes de anticuerpos felinos

Info

Publication number
CL2023001781A1
CL2023001781A1 CL2023001781A CL2023001781A CL2023001781A1 CL 2023001781 A1 CL2023001781 A1 CL 2023001781A1 CL 2023001781 A CL2023001781 A CL 2023001781A CL 2023001781 A CL2023001781 A CL 2023001781A CL 2023001781 A1 CL2023001781 A1 CL 2023001781A1
Authority
CL
Chile
Prior art keywords
mutations
constant regions
feline
feline antibodies
antibodies
Prior art date
Application number
CL2023001781A
Other languages
English (en)
Inventor
Marie Bergeron Lisa
Luis CAMPOS Henry
Ann Marie Lightle Sandra
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2023001781A1 publication Critical patent/CL2023001781A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere generalmente a variantes de anticuerpos felinos y usos de estos. Específicamente, la invención se refiere a mutaciones en la región constante de anticuerpo felino para mejorar diversas características.
CL2023001781A 2020-12-18 2023-06-16 Mutaciones en regiones constantes de anticuerpos felinos CL2023001781A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063127313P 2020-12-18 2020-12-18

Publications (1)

Publication Number Publication Date
CL2023001781A1 true CL2023001781A1 (es) 2023-12-22

Family

ID=79730576

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001781A CL2023001781A1 (es) 2020-12-18 2023-06-16 Mutaciones en regiones constantes de anticuerpos felinos

Country Status (14)

Country Link
EP (1) EP4263596A1 (es)
JP (1) JP2024503212A (es)
KR (1) KR20230121056A (es)
CN (1) CN116547298A (es)
AU (1) AU2021400322A1 (es)
CA (1) CA3202074A1 (es)
CL (1) CL2023001781A1 (es)
CO (1) CO2023007829A2 (es)
EC (1) ECSP23044286A (es)
IL (1) IL303732A (es)
MX (1) MX2023006898A (es)
PE (1) PE20231640A1 (es)
TW (1) TW202233687A (es)
WO (1) WO2022133252A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024050491A2 (en) * 2022-09-02 2024-03-07 Zoetis Services Llc Porcine antibody mutants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
BRPI0515230A (pt) 2004-08-19 2008-07-15 Genentech Inc polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2019360271A1 (en) * 2018-10-18 2021-04-29 Elanco Us Inc. Fc variants with altered binding to neonatal Fc receptor (FcRn) for veterinary use
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体

Also Published As

Publication number Publication date
CA3202074A1 (en) 2022-06-23
MX2023006898A (es) 2023-06-26
TW202233687A (zh) 2022-09-01
JP2024503212A (ja) 2024-01-25
ECSP23044286A (es) 2023-07-31
AU2021400322A1 (en) 2023-06-22
CN116547298A (zh) 2023-08-04
IL303732A (en) 2023-08-01
PE20231640A1 (es) 2023-10-16
WO2022133252A1 (en) 2022-06-23
KR20230121056A (ko) 2023-08-17
CO2023007829A2 (es) 2023-07-21
EP4263596A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
CL2023003377A1 (es) Variantes de anticuerpos caninos
CL2023003376A1 (es) Variantes de anticuerpos felinos
EA202092847A1 (ru) Антитела к cd3 и их применение
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
CL2023001781A1 (es) Mutaciones en regiones constantes de anticuerpos felinos
CL2023000895A1 (es) Receptores quiméricos de dll3 y métodos para su uso
PE20141060A1 (es) Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
CO2023007146A2 (es) Variantes de anticuerpos bovinos
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
ECSP23057156A (es) Mutaciones en regiones constantes de anticuerpos caninos
ECSP23030271A (es) Variantes de anticuerpos caninos
EA201992776A1 (ru) Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
EA202190382A1 (ru) Фармацевтические составы на основе маскированных антител
PE20230259A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
ECSP23030307A (es) Variantes de anticuerpos felinos
EA201992365A1 (ru) Микрофлюидные диффузионные устройства и системы, а также способы их изготовления и применения
EA202192101A1 (ru) Соединения и их применение
EA202091973A1 (ru) Конструкции слитых белков, содержащие анти-muc1 антитело и il-15
PE20240080A1 (es) Anticuerpos anti-hbv y metodos de uso
EA201992186A1 (ru) Антитела к par2 и пути их применения
CL2021002836A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos (divisional de la solicitud n° 201900424)
EA202192113A1 (ru) Антитела, распознающие тау
TR202104726A2 (tr) Köfte form maki̇nasinda yeni̇li̇k